RCUS · NYSE
Arcus Biosciences (RCUS) Stock Price & Fundamentals
Arcus Biosciences (RCUS) closed at $331.12 on Oct 9, 2026, up 1.28% from the previous close of $326.93.
Share price, past year
1Y −2.24%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $331.12 |
| Sep 30, 2026 | $329.60 |
| Aug 31, 2026 | $339.33 |
| Jul 31, 2026 | $349.27 |
| Jun 30, 2026 | $344.75 |
| May 29, 2026 | $339.06 |
| Apr 30, 2026 | $343.19 |
| Mar 31, 2026 | $336.87 |
| Feb 27, 2026 | $354.67 |
| Jan 30, 2026 | $311.27 |
| Dec 31, 2025 | $305.73 |
| Nov 28, 2025 | $314.74 |
| Oct 31, 2025 | $323.96 |
Key statistics
- Market cap
- $42.05B
- P/E (TTM)
- —
- EPS (TTM)
- −$3.89
- Revenue (TTM)
- $117.00M
- Net income (TTM)
- −$460.00M
- Shares outstanding
- 127M
- Dividend yield
- —
- 52-week range
- $291.93 – $359.83
Arcus Biosciences's market cap is $42.05B, based on a share price of $331.12 and 127M shares outstanding as of Jun 30, 2026.
Financials
Arcus Biosciences reported revenue of $247.00M for fiscal 2025, down 4.26% from fiscal 2024.
Arcus Biosciences reported a net loss of $353.00M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $247.00M | −4.3% | −$353.00M | −142.9% | −$3.29 | −$484.00M |
| FY2024ended Dec 31, 2024 | $258.00M | +120.5% | −$283.00M | −109.7% | −$3.14 | −$176.00M |
| FY2023ended Dec 31, 2023 | $117.00M | +4.5% | −$307.00M | −262.4% | −$4.15 | −$330.00M |
| FY2022ended Dec 31, 2022 | $112.00M | −70.8% | −$267.00M | −238.4% | −$3.71 | $432.00M |
| FY2021ended Dec 31, 2021 | $383.00M | +391.0% | $53.00M | 13.8% | $0.71 | −$282.00M |
| FY2020ended Dec 31, 2020 | $78.00M | +420.0% | −$123.00M | −157.7% | −$2.24 | $108.00M |
| FY2019ended Dec 31, 2019 | $15.00M | +79.6% | −$84.71M | −564.7% | −$1.93 | −$75.39M |
| FY2018ended Dec 31, 2018 | $8.35M | +491.2% | −$49.59M | −593.7% | −$1.43 | −$46.74M |
| FY2017ended Dec 31, 2017 | $1.41M | — | −$53.08M | −3,756.7% | −$29.03 | −$30.57M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $41.00M | −$91.00M | −$0.72 |
| Q1 FY2026ended Mar 31, 2026 | $17.00M | −$128.00M | −$1.02 |
| Q4 FY2025ended Dec 31, 2025 | $33.00M | −$106.00M | −$0.88 |
| Q3 FY2025ended Sep 30, 2025 | $26.00M | −$135.00M | −$1.27 |
| Q2 FY2025ended Jun 30, 2025 | $160.00M | $0.00 | $0.00 |
| Q1 FY2025ended Mar 31, 2025 | $28.00M | −$112.00M | −$1.14 |
| Q4 FY2024ended Dec 31, 2024 | $26.00M | −$94.00M | −$1.07 |
| Q3 FY2024ended Sep 30, 2024 | $48.00M | −$92.00M | −$1.00 |
Company profile
- Name
- Arcus Biosciences, Inc.
- Ticker
- RCUS
- Exchange
- NYSE
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 3928 Point Eden Way, Hayward, CA 94545
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001724521
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- Jun 12, 2026
- May 5, 2026
- May 5, 2026
- Apr 20, 2026
- Mar 23, 2026
- Feb 25, 2026
Frequently asked questions
What is Arcus Biosciences's stock price?
Arcus Biosciences (RCUS) closed at $331.12 on Oct 9, 2026, up 1.28% from the previous close of $326.93.
What is Arcus Biosciences's market cap?
Arcus Biosciences's market cap is $42.05B, based on a share price of $331.12 and 127M shares outstanding as of Jun 30, 2026.
How much revenue does Arcus Biosciences make?
Arcus Biosciences reported revenue of $247.00M for fiscal 2025, down 4.26% from fiscal 2024.
Does Arcus Biosciences pay a dividend?
Arcus Biosciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Arcus Biosciences, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures